drugset / Trial / NCT04730947

Dapagliflozin (DAPA) Effects in HFpEF

NCT04730947 ↗

Phase 2 Completed 38 enrolled Mayo Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and improve cardiac metabolism.

Timeline

Start
2021-02-24
Primary completion
2022-11-17
Completion
2022-11-17

Outcome

Met primary endpoint

paper reduction in the primary end point of change in PCWP at rest and during exercise at 24 weeks relative to treatment with placebo PMID 37534453 ↗

registry MEAN Dapagliflozin Group: -6.6 (Standard Deviation 7.2) mmHg NCT04730947 ↗

registry analysis (superiority test); Dapagliflozin Group vs Placebo Group; p = 0.027; t-test, 2 sided NCT04730947 ↗

registry analysis (superiority test); Dapagliflozin Group vs Placebo Group; p = 0.029; t-test, 2 sided NCT04730947 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral